Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
03 nov. 2023 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended September 30, 2023, and provided a business update.
Transforming Skin Care: Atopic Eczema Treatment Market Size Predicted to Flourish to USD 13 Billion by 2030, with a 7.14% CAGR
22 sept. 2023 08h02 HE
|
Zion Market Research
New York, NY, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Atopic Eczema Treatment Market - By Drug Class (Biologics And PDE4 Inhibitors), By...
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
19 sept. 2023 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trialsFor the primary endpoint, 25.4% of children...
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
12 sept. 2023 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United StatesIn pivotal Phase 3 trials, roflumilast cream demonstrated...
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
07 sept. 2023 08h15 HE
|
Arcutis Biotherapeutics, Inc.
Results for adults and children ages 6 years and older from INTEGUMENT-OLE long-term extension trial highlight that 46.1% and 51.0% of patients who rolled over from the roflumilast cream treatment arm...
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
11 juil. 2023 09h58 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...
Sublingual Allergy Immunotherapy Market Size to Surpass US$ 1.02 billion by 2033 at a CAGR of 9.1%| Persistence Market Research
12 juin 2023 09h45 HE
|
Persistence Market Research
New York, June 12, 2023 (GLOBE NEWSWIRE) -- The sublingual allergy immunotherapy (SLIT) market has been experiencing steady growth in recent years due to increasing prevalence of allergies and...
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
30 mai 2023 04h00 HE
|
AKAMPION
Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late...
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
09 mai 2023 16h02 HE
|
Arcutis Biotherapeutics, Inc.
Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarterContinued expansion of commercial...
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
02 mai 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
A total of 652 children, ages 2 to 5, were enrolled in the studyTopline data expected in the third quarterAtopic dermatitis (AD) affects approximately 26 million adults and children in the United...